Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis

Table 2 ORs for remission after 1 year of follow-up

Model	Variable	CD8⁺ T cells		CD4⁺ T cells		CD19⁺ B cells		CD14⁺ monocytes
		OR (95% CI)	p Value	OR (95% CI)	p Value	OR (95% CI)	p Value	OR (95% CI)	p Value
Unadjusted	pJAK1	0.57 (0.25–1.18)	0.14	0.47 (0.18–1.03)	0.053	0.75 (0.36–1.49)	0.42	0.78 (0.38–1.56)	0.49
	pJAK2	0.96 (0.48–1.89)	0.90	0.63 (0.30–1.26)	0.20	0.95 (0.48–1.88)	0.88	0.55 (0.25–1.10)	0.092
	pJAK3	3.01 (1.20–9.55)	0.017	2.40 (1.08–6.11)	0.032	2.19 (1.03–5.32)	0.044	1.84 (0.91–4.00)	0.094
	pTyk2	1.34 (0.64–3.24)	0.49	1.23 (0.61–2.84)	0.61	1.46 (0.65–3.78)	0.44	0.92 (0.46–1.82)	0.80
Adjusted^a	pJAK1	0.42 (0.13–1.14)	0.083	0.46 (0.16–1.09)	0.077	0.68 (0.30–1.49)	0.32	0.84 (0.36–1.94)	0.70
	pJAK2	0.97 (0.46–2.1)	0.94	0.53 (0.25–1.20)	0.14	0.66 (0.29–1.42)	0.29	0.42 (0.16–0.96)	0.034
	pJAK3	3.87 (1.33–16.65)	0.009	2.73 (1.16–7.90)	0.017	2.87 (1.11–8.87)	0.029	2.22 (1.01–5.31)	0.045
	pTyk2	1.40 (0.64–3.25)	0.45	1.32 (0.62–3.05)	0.52	1.47 (0.63–3.47)	0.44	0.92 (0.45–1.93)	0.83

pJAK Phosphorylated Janus kinase, Tyk Tyrosine kinase
^a The models are adjusted for anti-citrullinated protein antibody, number of disease-modifying antirheumatic drugs at entry, smoking, and white blood cell count. ORs are calculated per 1 SD

ISSN: 1478-6362